PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases

被引:5
|
作者
Sadetski, Igor [1 ]
Eshet, Yael [2 ]
Kaidar-Person, Orit [1 ]
Amit, Uri [1 ]
Domachevsky, Liran [2 ]
Davidson, Tima [2 ]
Weiss, Ilana [1 ]
Ben Ayun, Maoz [1 ]
Symon, Zvi [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Radiat Oncol, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Nucl Med, Tel Aviv, Israel
关键词
PSMA; PET; prostate; radiation; stereotactic; SBRT; cancer; BODY RADIATION-THERAPY; RECURRENCE; CRITERIA; PERCIST; RECIST;
D O I
10.5603/RPOR.a2021.0071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In the current study we evaluated Ga-68 PSMA PET/CT to measure local control of bone metastasis in oligometastatic prostate cancer patients treated with SBRT. Materials and methods: After the institutional review board approval, a retrospective review of medical records of consecutive prostate cancer patients treated between 2014 and 2018 was conducted. Only medical records of patients that were treated with SBRT for bone metastasis and had pre-and post-SBRT Ga-68 PSMA PET/CT scans were included in our study. Data extracted from the medical files included patient-related (age), disease-related (Gleason score, site of metastasis), and treatment-related factors and outcomes. Results: During the study period, a total of 12 patients (15 lesions) were included, with a median age of 73 years. The median follow-up was 26.5 months (range 13-45 months). Median time Ga-68 PSMA PET/CT follow up was 17.0 months (range 3-39 months). The median pre-treatment PSA was 2 ng/mL (range 0.56-44 ng/mL) vs. post treatment PSA nadir of 0.01 ng/mL (0.01-4.32) with a median timeto nadir of 7 months (range, 2-12). Local control was 93% during the follow up period and there was correlation with PSMA avidity on PET. None patients developed recurrences in the treated bone. None of the patients had grade 3 or more toxicities during follow-up. Conclusions: SBRT is a highly effective and safe method for treatment of prostate cancer bone metastases. More studies are required to determine if SBRT provides greater clinical benefit than standard fractionation for oligometastatic prostate cancer patients. Ga-68 PSMA PET/CT should be further investigated for delineation and follow-up.
引用
收藏
页码:528 / 534
页数:7
相关论文
共 50 条
  • [41] Evaluation of the optimal imaging protocol for [18F] PSMA PET-CT to detect bone metastases in prostate cancer patients
    Ventura, D.
    Bredensteiner, L.
    Rassek, P.
    Schaefers, M.
    Boegemann, M.
    Schindler, P.
    Weckesser, M.
    Rahbar, K.
    Roll, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S702 - S702
  • [42] 68Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
    Jonathan Damjanovic
    Jan-Carlo Janssen
    Christian Furth
    Gerd Diederichs
    Thula Walter
    Holger Amthauer
    Marcus R. Makowski
    Cancer Imaging, 18
  • [43] Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients
    Mohsen Beheshti
    Werner Langsteger
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 910 - 911
  • [44] Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients
    Beheshti, Mohsen
    Langsteger, Werner
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (05) : 910 - 911
  • [45] Dual time psma pet/ct with diuretics and contrast to detect prostate cancer pelvic metastases: is there a benefit?
    Tognoli, T.
    Camacho, M. R. F.
    Santos, A. O.
    Lima, M. C. L.
    Amorim, B. J.
    Ferreira, U.
    Etchebehere, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S534 - S534
  • [46] Artificial intelligence for the detection of primary tumour, recurrence and metastases in PSMA PET-CT in prostate cancer
    Tragardh, E.
    Enqvist, O.
    Ulen, J.
    Jogi, J.
    Edenbrandt, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S270 - S270
  • [47] 68Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
    Damjanovic, Jonathan
    Janssen, Jan-Carlo
    Furth, Christian
    Diederichs, Gerd
    Walter, Thula
    Amthauer, Holger
    Makowski, Marcus R.
    CANCER IMAGING, 2018, 18
  • [48] Atypical Presentation of Liver Metastases of Prostate Cancer in 68Ga-PSMA-11 PET/CT
    Stanzel, Susanne
    Weitzer, Friedrich
    Janek, Elmar
    Plhak, Elisabeth
    Aigner, Reingard M.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : 1064 - 1065
  • [49] Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
    Regula, Naresh
    Kostaras, Vasileios
    Johansson, Silvia
    Trampal, Carlos
    Lindstrom, Elin
    Lubberink, Mark
    Iyer, Victor
    Velikyan, Irina
    Sorensen, Jens
    EUROPEAN JOURNAL OF HYBRID IMAGING, 2022, 6 (01):
  • [50] Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
    Naresh Regula
    Vasileios Kostaras
    Silvia Johansson
    Carlos Trampal
    Elin Lindström
    Mark Lubberink
    Victor Iyer
    Irina Velikyan
    Jens Sörensen
    European Journal of Hybrid Imaging, 6